Mode
Text Size
Log in / Sign up
Phase 4 N=80 Randomized Treatment

Recovery and Analgesia After Surgery for Gynecological Cancer

Gynecological Cancer

Enrolled (actual)
80
Serious AEs
11.3%
Results posted
Sep 2019
Primary outcome: Primary: Length of Stay — 4.3; 3.3 days

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Epidural (Drug); Intrathecal (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Lena Nilsson
Primary completion
Apr 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Length of Stay
4.3; 3.3
SECONDARY
Change in Quality of Life
44; 45; 39; 38; 46; 46

Summary

The purpose of the study is to compare epidural analgesia and intrathecal analgesia for explorative laparotomy through a middle-line incision for gynecological cancer in a fast track program to se if there is any difference in recovery. Length of stay is analyzed together with self-rate quality of life.

Eligibility Criteria

Inclusion Criteria

  • Women with gynecological cancer (suspected or verified) planned for explorative laparotomy through a middle-line incision with a curative purpose.
  • WHO performance status < 2.
  • American Society of Anesthesiologists class 1-2.
  • Women that understand and can express themselves in Swedish.
  • Women that after verbal and written information accept participation in the study and have signed an informed consent.

Exclusion Criteria

  • Women where surgery is expected to include part/s, other than the abdominal surgery, where intrathecal or epidural analgesia is not expected to be effective
  • Women with contra indications for intrathecal or epidural anesthesia.
  • Women who are physically disabled and therefore nor expected to be mobilized on the day after surgery in the same way as non-disabled.
  • Women with a mental retardation that makes it impossible to fill in the relevant questionnaires or makes it impossible to understand the meaning of participation, or if it is ethically doubtful to include the woman.
  • Women with psychiatric or mental disorder that according to the responsible physician makes it unsuitable to participate in the study .
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02026687). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search